Skeletal muscle anabolism is a side effect of therapy with the MEK inhibitor: selumetinib in patients with cholangiocarcinoma
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Cancer cachexia is characterised by skeletal muscle wasting; however, potential for muscle anabolism in patients with advanced cancer is unproven. METHODS: Quantitative analysis of computed tomography images for loss/gain of muscle in cholangiocarcinoma patients receiving selumetinib (AZD6244; ARRY-142886) in a Phase II study, compared with a separate standard therapy group. Selumetinib is an inhibitor of mitogen-activated protein/extracellular signal-regulated kinase and of interleukin-6 secretion, a putative mediator of muscle wasting. RESULTS: Overall, 84.2% of patients gained muscle after initiating selumetinib; mean overall gain of total lumbar muscle cross-sectional area was 13.6 cm(2)/100 days (∼2.3 kg on a whole-body basis). Cholangiocarcinoma patients who began standard treatment were markedly catabolic, with overall muscle loss of -7.3 cm(2)/100 days (∼1.2 kg) and by contrast only 16.7% of these patients gained muscle. CONCLUSION: Our findings suggest that selumetinib promotes muscle gain in patients with cholangiocarcinoma. Specific mechanisms and relevance for cachexia therapy remain to be investigated.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
RETRACTED: Targeting MEK induces myeloma-cell cytotoxicity and inhibits osteoclastogenesis
Tai, Y.-T., Fulciniti, M., Hideshima, T., Song, W., Leiba, M., Li, X.-F., Rumizen, M., Burger, P., Morrison, A., Podar, K., et al. (2007) · Blood · doi:10.1182/blood-2007-03-081240 · Cited by 109 · cited 6×
“Future randomised trials with this group of agents should include prospective assessment of inflammatory markers such as IL-6 and other cytokines implicated in cachexia, as well as outcomes that may reveal benefits of skeletal muscle gain.”
BackgroundMethodInfluentialRetractedPrado, C. M., Lieffers, J. R., McCargar, L. J., Reiman, T., Sawyer, M. B., Martin, L., & Baracos, V. E. (2008) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70153-0 · Cited by 3,238
Self-citationBodine, S. C., Stitt, T. N., Gonzalez, M., Kline, W. O., Stover, G. L., Bauerlein, R., Zlotchenko, E., Scrimgeour, A., Lawrence, J. C., Glass, D. J., et al. (2001) · Nature Cell Biology · doi:10.1038/ncb1101-1014 · Cited by 2,752
Mourtzakis, M., Prado, C. M. M., Lieffers, J. R., Reiman, T., McCargar, L. J., & Baracos, V. E. (2008) · Applied Physiology, Nutrition, and Metabolism · doi:10.1139/h08-075 · Cited by 2,224 · cited 3×
“5% (Mourtzakis et al, 2008) with a minimum detectable change of approximately 3 cm2.”
BackgroundMethodSelf-citationShen, W., Punyanitya, M., Wang, Z., Gallagher, D., St.-Onge, M.-P., Albu, J., Heymsfield, S. B., & Heshka, S. (2004) · Journal of Applied Physiology · doi:10.1152/japplphysiol.00744.2004 · Cited by 1,692 · cited 3×
“For adipose tissue, categories were based on the equivalence of 14.7 cm2 total fat at L3 and 1 kg tissue on a whole-body basis (Shen et al, 2004).”
BackgroundMethodInfluentialDodson, S., Baracos, V. E., Jatoi, A., Evans, W. J., Cella, D., Dalton, J. T., & Steiner, M. S. (2011) · Annual Review of Medicine · doi:10.1146/annurev-med-061509-131248 · Cited by 319 · cited 1×
“Muscle wasting is a defining feature of cancer cachexia and has major impacts on physical and respiratory function, immunity, chemotherapy response and overall survival (MacDonald et al, 2003; Prado et al, 2008, 2009; Saini et al, 2009; Dodson et al, 2011).”
BackgroundSelf-citationBruce, C. R., & Dyck, D. J. (2004) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00150.2004 · Cited by 178
Powerful signals for weak muscles
Saini, A., Faulkner, S., Al-Shanti, N., & Stewart, C. (2009) · Ageing Research Reviews · doi:10.1016/j.arr.2009.02.001 · Cited by 109 · cited 1×
“Muscle wasting is a defining feature of cancer cachexia and has major impacts on physical and respiratory function, immunity, chemotherapy response and overall survival (MacDonald et al, 2003; Prado et al, 2008, 2009; Saini et al, 2009; Dodson et al, 2011).”
Background
Cited by
Baracos, V. E., Martin, L., Korc, M., Guttridge, D. C., & Fearon, K. C. H. (2018) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2017.105 · Cited by 1,738
Self-citationUnderstanding the mechanisms and treatment options in cancer cachexia
Fearon, K., Arends, J., & Baracos, V. (2013) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2012.209 · Cited by 940
Self-citationBlauwhoff-Buskermolen, S., Versteeg, K. S., de van der Schueren, M. A. E., den Braver, N. R., Berkhof, J., Langius, J. A. E., & Verheul, H. M. W. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.63.6043 · Cited by 378
Understanding, recognizing, and managing toxicities of targeted anticancer therapies
Dy, G. K., & Adjei, A. A. (2013) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21184 · Cited by 331
Bozzetti, F. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx271 · Cited by 323
Metadata
- Authors
- Prado, C. M. M., Bekaii-Saab, T., Doyle, L. A., Shrestha, S., Ghosh, S., Baracos, V. E., & Sawyer, M. B.
- Venue
- British Journal of Cancer
- Published
- 2012-04-17
- Volume
- 106
- Issue
- 10
- Pages
- 1583-1586
- ISSN
- 0007-0920 (ISSN-L)
- 1532-1827
- OpenAlex
- W1978713285
- Cited by
- 106
- References
- 8
- FWCI
- 5.47
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Skeletal muscle anabolism is a side effect of therapy with the MEK inhibitor: selumetinib in patients with cholangiocarcinoma. https://app.cochat.ai/papers/10.1038/bjc.2012.144
- The paper
- Prado, C. M. M., Bekaii-Saab, T., Doyle, L. A., Shrestha, S., Ghosh, S., Baracos, V. E., & Sawyer, M. B. (2012). Skeletal muscle anabolism is a side effect of therapy with the MEK inhibitor: selumetinib in patients with cholangiocarcinoma. British Journal of Cancer. https://doi.org/10.1038/bjc.2012.144
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.